Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Vaxcyte, Inc.NASDAQ: PCVX
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt remains negative
Q2 FY2026 net debt was -$67.75M, compared with -$220.9M a year earlier.
Context
- Net debt amounted to 2.2% of total assets at the end of Q2 FY2026, down 4.5 pp from a year earlier.
- Net debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +69.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 54.88M USD
- Year-over-year change
- +117.3%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.88M | +117.3% |
| FY2024 | 2024-12-31 | (316.77M) | +14.0% |
| FY2023 | 2023-12-31 | (368.23M) | +54.9% |
| FY2022 | 2022-12-31 | (816.72M) | -1464.5% |
| FY2021 | 2021-12-31 | (52.2M) | — |
Net Debt vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +69.3% is the 5th highest of 9, against a peer median of +37.2%.
- Net debt amounts to 2.2% of total assets for PCVX, versus a peer median of 26.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $62.22B USD | +3.4% | +24.4% | 30.9% | |
| Jun 2026 | £15.04B GBP | -20.2% | -6.1% | 24.5% | |
| Sep 2026 | $2.98B USD | +1043.3% | — | 22.2% | |
| Sep 2026 | $824.44M USD | +71.0% | +8.5% | 135.3% | |
| Mar 2026 | €104.35M EUR | +79.4% | — | 28.0% | |
| Mar 2026 | $66.7M USD | +292.3% | — | 6.4% | |
| Jun 2026 | -$67.75M USD | +69.3% | — | 2.2% | |
| Mar 2026 | -$180.51M USD | -1.7% | — | 17.6% | |
| Mar 2026 | -$187.39M USD | -7.5% | — | 76.4% | |
| Peer median (excluding PCVX) | — | +37.2% | +8.5% | 26.3% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 68.99M | 834.66M | 397.45M | 387.88M | 173.96M |
| Short-term Investments | 176.99M | 96.72M | 682.78M | 1.36B | 1.39B |
| Net Receivables | 0 | 0 | 3.61M | 20.66M | 46.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 5.96M | 20.12M | 2.8M |
| Total Current Assets | 256.35M | 942.56M | 1.1B | 1.79B | 1.63B |
| Property, Plant & Equipment (Net) | 35.91M | 31.65M | 110.62M | 270.15M | 491.72M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 27.12M | 26.55M | 162.68M | 1.39B | 883.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 43.25M |
| Other Non-current Assets | 4.96M | 5.43M | 38.67M | 65.68M | 508K |
| Total Non-current Assets | 67.99M | 63.62M | 311.96M | 1.72B | 1.42B |
| Total Assets | 324.34M | 1.01B | 1.41B | 3.51B | 3.05B |
| Account Payables | 6.76M | 9.8M | 14.59M | 48.45M | 70.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 6.12M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.46M | 1.18M | 11.06M | 20.56M | 105.72M |
| Total Current Liabilities | 28.72M | 40.53M | 145.34M | 140.18M | 205.75M |
| Long-term Debt | 0 | 0 | 0 | 0 | 111.36M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 43.25M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 96K | 9K | 0 | 100K | (111.26M) |
| Total Non-current Liabilities | 11.6M | 12.04M | 22.11M | 65.32M | 154.7M |
| Total Liabilities | 40.32M | 52.57M | 167.45M | 205.5M | 360.46M |
| Common Stock | 56K | 82K | 98K | 128K | 134K |
| Retained Earnings | (298.64M) | (522.13M) | (924.39M) | (1.39B) | (2.15B) |
| Accumulated OCI | (241K) | (361K) | 179K | (3.87M) | 1.59M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.02M | 953.61M | 1.24B | 3.31B | 2.69B |
| Total Debt | 16.78M | 17.94M | 29.22M | 71.11M | 228.84M |
| Net Debt | (52.2M) | (816.72M) | (368.23M) | (316.77M) | 54.88M |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.